Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007, investing in early-stage companies developing novel human therapeutics. Based in Copenhagen, it supports scientific, clinical and business development through its investment team and external Business Development Advisory Board. Its neuroscience investments include Neumirna Therapeutics, developing RNA therapies for neurological disorders, and Synendos Therapeutics, developing endocannabinoid-system medicines for central nervous system disorders. Its funds also include historical medical technology and diagnostics investments.
Founded
—
Type
Venture capital
Funds4
Sunstone Life Science Ventures Fund I—€200M
Established in 2007; therapeutics, medical technology and diagnostics. Manager reports total committed capital and states the fund is no longer making new investments. Exact closing date is unpublished.
Sunstone Life Science Ventures Fund II—€86M
Established in 2007; therapeutics, medical technology and diagnostics; invested in 12 new portfolio companies. Manager reports total committed capital and states the fund is no longer making new investments. Exact closing date is unpublished.
Sunstone Life Science Ventures Fund III—€80M
Established in 2012; therapeutics and medical technology; invested in 11 new portfolio companies. Manager reports total committed capital and states the fund is no longer making new investments. Exact closing date is unpublished.
Sunstone Life Science Ventures Fund IV—€92M
Established in 2019; focused entirely on therapeutics. Manager reports total committed capital and states the fund is no longer making new investments. Exact closing date is unpublished.